Last Updated | 8 April 2026

T2020-006

A Phase I Study of Tagraxofusp With or Without Chemotherapy in paediatric Patients with Relapsed or Refractory CD123 Expressing Hematologic Malignancies
External Registry
Site Status Children's Hospital at Westmead Sydney Children's Hospital Royal Children's Hospital
Queensland Children's Hospital (QLD)
John Hunter Children's Hospital (NSW)
Sydney Children's Hospital (NSW)
Monash Health Clayton (VIC)
Royal Children's Hospital (VIC)
Women's and Children's Hospital (SA)
Perth Children's Hospital (WA)
Royal Hobart Hospital (TAS)
Children's Hospital at Westmead (NSW)
Starship Children's Hospital (NZ)
Christchurch Hospital (NZ)
Preparing to Open
Open
Temporarily Closed
Closed
Complete
Adult Sites These sites are not monitored. Status may vary.
Diagnosis Stage Relapsed/Refractory
National Sponsor Therapeutic Advances in Childhood Leukemia Consortium
Open Date 11/11/2022
Conditions Acute lymphoblastic leukemia
Acute myeloid leukemia
Myelodysplastic syndrome
Mixed phenotype acute leukemia
Acute undifferentiated leukemia
Blastic plasmacytoid dendritic cell neoplasm
Hodgkin lymphoma
Non-Hodgkin lymphoma
Patient Range 1 year21 years
Disease Type Leukaemia / Lymphoma / Blood Disorders
Study Type Interventional
International Sponsor N/A

Join our newsletter

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Email info@anzchog.org   |  

Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168

ANZCHOG acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait Islander cultures, and to Elders both past and present. We acknowledge Māori as tangata whenua of Aotearoa New Zealand and as Treaty partners with the Crown as agreed in Te Tiriti o Waitangi. 

We are committed to creating a safe and welcoming environment that embraces all backgrounds, cultures, sexualities, genders and abilities.